We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Intrauterine Lidocaine Infusion for Essure Sterilization Procedures

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00613834
Recruitment Status : Completed
First Posted : February 13, 2008
Last Update Posted : February 13, 2012
Information provided by (Responsible Party):

Study Description
Brief Summary:
The purpose of this study is to assess the level of pain women experience with an Essure procedure and the effect that lidocaine might have on that pain. We will also assess the absorption of lidocaine in the uterus by measuring lidocaine levels in the blood.

Condition or disease Intervention/treatment
Pain Drug: Lidocaine Drug: Sterile Saline

Detailed Description:

We intend to conduct a randomized, blinded, and placebo- controlled clinical trial at Oregon Health and Science University and Planned Parenthood of the Columbia Willamette to determine if intrauterine lidocaine infusion will decrease the amount of pain subjects experience during and after Essure transcervical tubal sterilization.

We plan to enroll women who have selected Essure as their method of tubal sterilization who will be randomized to one of two groups on the days of their procedures. Subjects in Group 1, the treatment group, will receive a standard paracervical block with lidocaine intrauterine infusion and subjects in Group 2, the control group, will receive a standard paracervical block with saline intrauterine infusion. The subjects will be asked to rate their pain on a 100 mm VAS at five points during the procedure and once thirty minutes following the procedure. Subjects will also be asked to rate their overall satisfaction with their care prior to leaving the recovery room.

Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 58 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Intrauterine Lidocaine Infusion for Pain Management During Outpatient Essure Transcervical Tubal Sterilization Procedures
Study Start Date : May 2007
Primary Completion Date : June 2008
Study Completion Date : June 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Tubal Ligation
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: 1 Drug: Lidocaine
5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
Placebo Comparator: 2 Drug: Sterile Saline
5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes

Outcome Measures

Primary Outcome Measures :
  1. Intrauterine lidocaine and patient perceived pain with Essure tubal sterilization as compared to the standard paracervical block. [ Time Frame: After enrollment is complete ]

Secondary Outcome Measures :
  1. To measure the amount of pain experienced during outpatient Essure procedures in the placebo group. [ Time Frame: After enrollment is complete ]
  2. To determine whether intrauterine lidocaine results in greater satisfaction with the Essure tubal sterilization experience. [ Time Frame: After enrollment is complete ]
  3. To obtain safety data on the absorption of intrauterine lidocaine in the non-pregnant uterus. [ Time Frame: After enrollment is complete ]

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Female
  • Age 18 or older
  • Good general health, based on the opinion of the investigator
  • Voluntarily requesting permanent sterilization
  • Negative pregnancy test
  • Agree to premedication with ibuprofen and ativan
  • English speaking, or other language if an interpreter is available to be present at all points of the study procedure.
  • Willing and able to sign an informed consent
  • Willing to comply with the terms of the study

Exclusion Criteria:

  • Significant physical or mental health condition, based on the opinion of the investigator.
  • Positive pregnancy test
  • Request for IV/IM sedation prior to the start of the procedure
  • Refusal of ibuprofen, ativan, or paracervical block
  • Allergy to any study medication including lidocaine, ibuprofen, ativan, sodium bicarbonate
  • History of toxic reaction to local anesthetics
  • Known hepatic disease or liver dysfunction. (Lidocaine is metabolized by the liver.)
  • Weight less than 100 pounds. [Any patient weighing less than 100 pounds would receive more than the recommended dose for their weight (4.5 mg/kg or 2 mg/lb)].
  • Current participation in another research study which would interfere with the conduct of this study.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00613834

United States, Oregon
Planned Parenthood of the Columbia Willamette
Portland, Oregon, United States, 97206
Oregon Health & Science University
Portland, Oregon, United States, 97239
Sponsors and Collaborators
Oregon Health and Science University
Principal Investigator: Michelle M. Isley, M.D. Oregon Health and Science University
More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Michelle Isley, MD, Oregon Health and Science University
ClinicalTrials.gov Identifier: NCT00613834     History of Changes
Other Study ID Numbers: OHSU FAMPLAN 3343
First Posted: February 13, 2008    Key Record Dates
Last Update Posted: February 13, 2012
Last Verified: February 2012

Keywords provided by Michelle Isley, Oregon Health and Science University:
Essure sterilization
pain management
intrauterine lidocaine infusion

Additional relevant MeSH terms:
Anesthetics, Local
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Anti-Arrhythmia Agents
Voltage-Gated Sodium Channel Blockers
Sodium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Anti-Infective Agents